Literature DB >> 2140497

Autobacteriographic studies of clarithromycin and erythromycin in mice.

Y Kohno1, K Ohta, T Suwa, T Suga.   

Abstract

The antimicrobial activity of clarithromycin was compared with that of erythromycin in experimentally infected mice by whole-body autobacteriography. In mice with systemic staphylococcal infections, the number of vital microbes in the body was relatively low in the early period after oral administration of erythromycin, but increased thereafter to the levels found in nonmedicated control mice. On the other hand, with clarithromycin treatment, a significantly smaller number of microbes was evident throughout the body. The microbes were scarcely seen in the parenchyma of any organs during the examination period. This potent antimicrobial activity of clarithromycin compared with that of erythromycin was further demonstrated in mice with respiratory infections. On the other hand, to examine the distribution properties of both antibiotics in the whole body, an autoradiographic study was carried out with [N-methyl-14C]clarithromycin and [N-methyl-14C]erythromycin. Both labeled antibiotics were distributed widely throughout the body after oral administration in both uninfected control mice and mice with systemic infections. However, the radioactivity was more marked and persistent for [14C]clarithromycin than it was for [14C]erythromycin, particularly in the lungs. The observations described above indicate the superior in vivo antimicrobial activity of clarithromycin compared with that of erythromycin and suggest that the superiority of clarithromycin is largely attributed to its favorable distribution properties. The advantages of whole-body autobacteriography, coupled with whole-body autoradiography, are discussed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2140497      PMCID: PMC171644          DOI: 10.1128/AAC.34.4.562

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  [Experimental Pseudomonas pneumonia model in normal mice].

Authors:  S Kohno; K Sasayama; Y Doutsu; K Yamashita; N Shibuya; T Miyazaki; H Koga; H Nakazato; M Nagasawa; N Suyama
Journal:  Kansenshogaku Zasshi       Date:  1986-11

2.  Detection of Erysipelothrix insidiosa in mice by whole body autobacteriography.

Authors:  S Sakuma; M Sakuma; A Okaniwa; Y Sato
Journal:  Natl Inst Anim Health Q (Tokyo)       Date:  1973

3.  [The whole body autobacteriographic studies on the distribution of Staphylococcus aureus in mice].

Authors:  M Sakuma; S Awataguchi; Y Sato
Journal:  Yakugaku Zasshi       Date:  1970-09       Impact factor: 0.302

4.  Chemical modification of erythromycins. I. Synthesis and antibacterial activity of 6-O-methylerythromycins A.

Authors:  S Morimoto; Y Takahashi; Y Watanabe; S Omura
Journal:  J Antibiot (Tokyo)       Date:  1984-02       Impact factor: 2.649

5.  Erythromycin VI: kinetics of acid-catalyzed hydrolysis of erythromycin oxime and erythromycylamine.

Authors:  T Lazarevski; G Radobolja; S Djokić
Journal:  J Pharm Sci       Date:  1978-07       Impact factor: 3.534

6.  Metabolism of propionyl erythromycin lauryl sulfate. I. Fate of the propionyl erythromycin moiety in the rat.

Authors:  P J Murphy; T L Williams; R E McMahon; F J Marshall
Journal:  Drug Metab Dispos       Date:  1975 May-Jun       Impact factor: 3.922

7.  N-Didemethyl-n-propionyl-6,9;9, 12-erythromycin A-spiroketal, a new metabolite of erythromycin ethyl succinate in man.

Authors:  J Majer; R S Stanaszek; S L Mueller; G Marti
Journal:  Drug Metab Dispos       Date:  1978 Nov-Dec       Impact factor: 3.922

8.  The localization of Staphylococcus aureus in mice by whole-animal radioautography.

Authors:  P F Bonventre; J G Imhoff
Journal:  Am J Pathol       Date:  1966-01       Impact factor: 4.307

9.  Comparative pharmacokinetics of clarithromycin (TE-031), a new macrolide antibiotic, and erythromycin in rats.

Authors:  Y Kohno; H Yoshida; T Suwa; T Suga
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

10.  In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide.

Authors:  P B Fernandes; R Bailer; R Swanson; C W Hanson; E McDonald; N Ramer; D Hardy; N Shipkowitz; R R Bower; E Gade
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

View more
  4 in total

Review 1.  Clarithromycin clinical pharmacokinetics.

Authors:  F Fraschini; F Scaglione; G Demartini
Journal:  Clin Pharmacokinet       Date:  1993-09       Impact factor: 6.447

Review 2.  Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential.

Authors:  D H Peters; S P Clissold
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

3.  Influence of macrolide susceptibility on efficacies of clarithromycin and azithromycin against Streptococcus pneumoniae in a murine lung infection model.

Authors:  Holly L Hoffman; Michael E Klepser; Erika J Ernst; C Rosemarie Petzold; Loai Mohammed Sa'adah; Gary V Doern
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

4.  Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral doses.

Authors:  S Y Chu; L T Sennello; S T Bunnell; L L Varga; D S Wilson; R C Sonders
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.